Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
sumatriptan nasal powderThis study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age. Migraine Phase 3 À vérifier United States À vérifier
sumatriptan nasal powderThis study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age. Migraine Phase 3 À vérifier United States À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
sumatriptan nasal powder Migraine Phase 3 NCT03338920 Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents TERMINATED

Publications

0
MoléculeIndication / populationTitreJournalDate
Aucune publication.